e-learning
resources
Madrid 2019
Tuesday, 01.10.2019
Assessment and management of immune-mediated interstitial lung diseases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Antifibrotic treatment in 18 patients with chronic Hypersensitivity Pneumonitis
V. Tzilas (Athens, Greece), A. Tzouvelekis (Athens, Greece), E. Bouros (Athens, Greece), M. Katsaras (Athens, Greece), M. Ntassiou (Athens, Greece), T. Karampitsakos (Athens, Greece), D. Bouros (Athens, Greece)
Source:
International Congress 2019 – Assessment and management of immune-mediated interstitial lung diseases
Session:
Assessment and management of immune-mediated interstitial lung diseases
Session type:
Thematic Poster
Number:
4733
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
V. Tzilas (Athens, Greece), A. Tzouvelekis (Athens, Greece), E. Bouros (Athens, Greece), M. Katsaras (Athens, Greece), M. Ntassiou (Athens, Greece), T. Karampitsakos (Athens, Greece), D. Bouros (Athens, Greece). Antifibrotic treatment in 18 patients with chronic Hypersensitivity Pneumonitis. 4733
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Outcomes of immunosuppressive therapy in chronic hypersensitivity pneumonitis
Source: ERJ Open Res, 3 (3) 00016-2017; 10.1183/23120541.00016-2017
Year: 2017
Rituximab for the treatment of chronic hypersensitivity pneumonitis
Source: International Congress 2015 – Interstitial lung diseases I
Year: 2015
Hypersensitivity pneumonitis associated with the use of temozolomide
Source: Eur Respir J 2009; 33: 931-934
Year: 2009
Chronic inhaled corticosteroids in patients with bronchiectasis who suffer an exacerbation
Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations
Year: 2016
Diagnosis and management of chronic fibrotic hypersensitivity pneumonitis
Source: Virtual Congress 2020 – Diagnosis and management of chronic fibrotic hypersensitivity pneumonitis
Year: 2020
Chronic Hypersensitivity Pneumonitis and mortality: impact of comorbidities
Source: Virtual Congress 2020 – Clinical issues in granulomatous lung diseases
Year: 2020
Long-term safety of combination therapy with nintedanib and pirfenidone in Japanese patients with IPF
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Hypersensitivity pneumonitis associated with temozolomide
Source: Eur Respir J 2009; 33: 526
Year: 2009
Hypersensitivity pneumonitis caused by oral aspirin
Source: Annual Congress 2009 - Clinical aspects of inflammatory airways diseases
Year: 2009
Efficacy of short-term prednisolone treatment in patients with chronic eosinophilic pneumonia
Source: Eur Respir J 2015; 45: 1624-1631
Year: 2015
Effect of 2-Year therapy with Roflumilast in severe systemic inflammation in COPD with metabolic syndrome
Source: International Congress 2019 – Advances in COPD pharmacology
Year: 2019
Chronic Hypersensitivity pneumonitis: risks factors and therapeutic options
Source: Virtual Congress 2020 – Interstitial lung diseases
Year: 2020
Methotrexate as a single agent for the treatment of patients with progressive pulmonary sarcoidosis
Source: International Congress 2015 – Sarcoidosis: clinical
Year: 2015
Impact Prognostic impact of comorbidities in patients with chronic Hypersensitivity Pneumonitis
Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: from the bench to the bedside
Year: 2018
Anti-inflammatory therapy for sarcoidosis patients
Source: Annual Congress 2013 –Diffuse parenchymal lung disease III
Year: 2013
Impact of BAL lymphocytosis and honeycombing presence on corticosteroid treatment effect in Fibrotic Hypersensitivity Pneumonitis
Source: International Congress 2019 – Connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis: what’s new?
Year: 2019
Evaluation of methotrexate in the treatment of severe asthma
Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis
Year: 2015
Intravenous pulse doses of high-dose corticosteroid and cyclophosphamide in acute exacerbation of idiopathic pulmonary fibrosis
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Cyclophosphamide in steroid-refractory hypersensitivity pneumonitis and non-classifiable interstitial lung disease
Source: International Congress 2017 – Novel and old entities
Year: 2017
Mechanisms of exercise limitation in patients with chronic hypersensitivity pneumonitis
Source: ERJ Open Res, 4 (3) 00043-2018; 10.1183/23120541.00043-2018
Year: 2018
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept